Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Invested Capital (2016 - 2025)

Cytosorbents (CTSO) has disclosed Return on Invested Capital for 12 consecutive years, with 0.9% as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Return on Invested Capital changed N/A year-over-year to 0.9%, compared with a TTM value of 0.9% through Mar 2025, changed N/A, and an annual FY2024 reading of 0.77%, up 13.0% over the prior year.
  • Return on Invested Capital was 0.9% for Q1 2025 at Cytosorbents, up from 1.09% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.12% in Q1 2021 and bottomed at 1.09% in Q4 2024.
  • Average Return on Invested Capital over 5 years is 0.58%, with a median of 0.59% recorded in 2022.
  • The sharpest move saw Return on Invested Capital soared 47bps in 2021, then tumbled -58bps in 2022.
  • Year by year, Return on Invested Capital stood at 0.33% in 2021, then tumbled by -147bps to 0.82% in 2022, then dropped by -12bps to 0.91% in 2023, then fell by -19bps to 1.09% in 2024, then increased by 18bps to 0.9% in 2025.
  • Business Quant data shows Return on Invested Capital for CTSO at 0.9% in Q1 2025, 1.09% in Q4 2024, and 0.91% in Q4 2023.